A Study of SOM230 to Reduce the Risk of Fistulas, Leaks, and Abscesses After Pancreatic Surgery
[Protocol 09-039] |
Allen, Peter, MD |
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
[Protocol 11-194] |
Ginex, Pamela, RN, EDD |
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Pancreatic Cancer
[Protocol 10-083] |
Goodman, Karyn, MD |
A Phase IB Study of BKM120 plus MEK162 in Select Patients with Advanced Solid Tumors
[Protocol 11-117] |
Gounder, Mrinal, MD |
A Phase II Study of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer
[Protocol 12-011] |
Ilson, David, MD |
A Randomized Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) Treatment versus Conventional DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer
[Protocol 06-103] |
Janjigian, Yelena, MD |
A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
[Protocol 11-166] |
Janjigian, Yelena, MD |
Early Onset and Familial Gastric Cancer Registry
[Protocol 05-118] |
Kelsen, David, MD |
A Phase II Study of Ipilimumab versus Standard Chemotherapy after Initial Therapy in Patients with Inoperable or Advanced Gastric or Gastroesophageal Cancer
[Protocol 12-277] |
Ku, Geoffrey, MD |
Memorial Sloan-Kettering Cancer Center Pancreatic Tumor Registry
[Protocol 02-102] |
Kurtz, Robert, MD |
A Phase I/II Study of Gemcitabine, Cisplatin, and MEK162 as Initial Treatment for Advanced Bile Duct or Gallbladder Cancer
[Protocol 13-004] |
Lowery, Maeve, MD |
A Phase I/II Study of M402 in Combination with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
[Protocol 12-078] |
O'Reilly, Eileen, MD |
Two Phase II Studies of Veliparib for Pancreatic Cancer with a BRCA or PALB2 Mutation: Gemcitabine & Cisplatin with/without Veliparib in Untreated Pancreatic Cancer (Part I) & Veliparib Alone for Patients with Previously Treated Pancreatic Cancer (Part II
[Protocol 12-045] |
O'Reilly, Eileen, MD |
A Phase IB/II Study of OMP-59R5 with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
[Protocol 12-234] |
O'Reilly, Eileen, MD |
A Phase III Study of Everolimus versus Placebo in Patients with Neuroendocrine Tumors Originating in the Lungs or Gastrointestinal Tract: The RADIANT-4 Study
[Protocol 12-250] |
Reidy-Lagunes, Diane, MD |
A Prospective Study to Determine if Variations in Tissue Oxygenation Are Associated with Leak Rates after Esophagectomy
[Protocol 11-192] |
Rizk, Nabil, MD |
A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Cancer
[Protocol 11-037] |
Rizk, Nabil, MD |
Quality of Life Outcomes Following Minimally Invasive versus Open Esophagectomy for Esophageal Cancer
[Protocol 12-003] |
Sarkaria, Inderpal, MD |
A Phase II Study Evaluating the Addition of Trastuzumab to Standard Therapy for HER2-Positive Esophageal Cancers
[Protocol 12-094] |
Wu, Abraham, MD |
A Phase IB Dose-Escalation and Safety Study of LDE225 plus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Cancer
[Protocol 12-036] |
Yu, Kenneth, MD |
